William K. Oh, MD

About William K. Oh, MD

Dr. William K. Oh is Chief Medical Officer at PCF and also Clinical Professor of Medicine in the Division of Hematology and Medical Oncology at The Tisch Cancer Institute at Mount Sinai.

A leading clinician and investigator in the use of systemic treatments for prostate cancer, Dr. Oh has served as the principal investigator of multiple clinical trials in prostate cancer. In addition, he developed large clinical databases and specimen repositories for genitourinary cancers at both Harvard and Mount Sinai. He has authored more than 350 original articles, reviews and book chapters on topics relating to prostate, renal, bladder and testicular cancers. He has edited 3 books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology (ASCO), the American Cancer Society (ACS) and the American Urological Association (AUA), including the Guidelines Committee for Castration Resistant Prostate Cancer. He was inducted into the prestigious American Society for Clinical Investigation (ASCI) and has been repeatedly selected as a Top Doctor in New York Magazine as of 2023, and Castle Connolly, Best Doctors and Super Doctors through 2022. He was announced as a Top Asian American Pacific Islander (AAPI) Doctor in 2023.

Dr. Oh received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital in Boston and completed medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Oh was at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, MA for 14 years, where he served as Clinical Director of the Lank Center for Genitourinary Oncology and was founding Chair of the Data and Safety Monitoring Committee at the Dana-Farber/Harvard Cancer Center. Dr. Oh was also Chief of the Division of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai for 11 years through 2020. He also served as Deputy Director of the Tisch Cancer Institute at Mount Sinai, which he helped to achieve NCI designation. His most recent role was as CMO for Sema4, a publicly-traded genomics and health intelligence company.

View the Full Leadership Team here.